Genmab — Januar 2020

E_L

i very much doubt that is the real Markedskonsensus . Too high in my opinion...

kkjoel

Så hvad mener du markedskonsensus er, EL - 4,25?

E_L

possibly. if i had to guess i would say between 4 and 4.2. We will have a better idea after the market reaction to guidance on Feb 19

Bulder

Sjov peak C25 lavede der kl 16. Robotter i selvsving?

AaBforever

Fedt!!

Bulder

Vi kan da starte med recepttallet allerede nu. Det skal helst ikke under 165.

Bulder

Dec har 2 arbejdsdage mere end nov.

DevOp

Ja, men prøv at se 2018, der lå dec lavere end okt og
nov

Bulder

Bliver det lavere end nov, begynder det at stramme til.

KWC

Genmab Announces European Marketing Authorization for DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement

DARZALEX (daratumumab) approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Approval follows positive opinion by European Committee for Medicinal Produ

KWC

Copenhagen, Denmark; January 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for DARZALEX (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The EC approval follows a positive opinion issued for DARZALEX by the CHMP of the European Medicines Agency (EMA) in Decemb

KWC

“With this approval, newly diagnosed patients with multiple myeloma who are eligible for ASCT may have the opportunity for treatment with a DARZALEX-containing regimen. We are extremely pleased that DARZALEX has received this latest approval and we look forward to the combination of DARZALEX plus bortezomib, thalidomide and dexamethasone being launched in Europe,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The approval was based on the Phase III CASSIOPEIA (MMY3006) study

bikube

Skidt med recepttallene denne gang, vi får det færdige resultat fra JnJ samme dag. Og dagens nyhed om godkendelse i EU må trække lidt op.

bikube

Orv - Kan du huske det Pensionisten.

Bulder

Det var hurtigt godkendelsen kom. Kun 5 uger og med jul og nytår ind imellem.

E_L

i was thinking the exact same. Nice.

Bulder

And with Alcyone approved 1½ years ago we now have both transplant and non-transplant covered in the EU. Will probably add up sales numbers in 2020.

Bulder

They submitted application March 27 last year. So all in all it took a little less than 10 mths.

Solsen

https://www.bbc.com/news/health-51182451 Endnu en historie omkring en kur imod cancer. Lad da håbe at det denne gang er rigtigt.

peter12

Såvidt jeg kan se er det en gammel historie fra Basel (og ikke Cardiff). Nok lettere tænkt end gjort ? https://elifesciences.org/articles/24476